Antimicrobial resistance (AMR) now kills an estimated 1.27 million people annually worldwide — a toll that exceeds HIV/AIDS (864,000) and malaria (627,000) combined, according to the landmark 2022 Lancet global burden analysis. In the United States, the CDC estimates 2.8 million antibiotic-resistant infections occur per year, with 35,000 deaths and $20 billion in excess healthcare costs. The confluence of evolutionary pressure from antibiotic overuse, a thinning antimicrobial development pipeline, and global spread of resistance genes through mobile genetic elements has created what WHO describes as "one of the biggest threats to global health, food security, and development."
The ESKAPE Pathogens: Priority Threats
The ESKAPE pathogens — Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species — represent the primary cause of nosocomial infections and are virtually all developing resistance to last-resort antibiotics. Carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB) mortality rates of 40–70% in bloodstream infections reflect the absence of effective oral alternatives and the toxicity of polymyxin-based salvage regimens. New resistance mechanisms include: MCR genes conferring polymyxin resistance, NDM-1 (New Delhi metallo-beta-lactamase) conferring pan-resistance to beta-lactams, and OXA-48 carbapenemases spreading silently through hospital environments on mobile genetic elements.
New Agents in the Pipeline
Despite the dismal pipeline picture of the 2010s, 2023–2025 has seen several important approvals: Cefiderocol (Fetroja, Shionogi) — a siderophore cephalosporin with activity against carbapenem-resistant gram-negative bacteria including CRAB and CRE; Imipenem-cilastatin-relebactam (Recarbrio) for carbapenem-resistant Pseudomonas; and Sulopenem etzadroxil (Orlynvah) — the first oral carbapenem-class antibiotic, enabling step-down therapy for complicated UTIs without IV access. In clinical development: zoliflodacin (novel spiropyrimidinetrione for gonorrhea, addressing WHO priority pathogen) and phage therapy trials for Mycobacterium abscessus lung infections in CF patients.
Antimicrobial Stewardship: The Evidence Base
Antimicrobial stewardship programs (ASPs) are now mandated by The Joint Commission and CMS for accredited US hospitals. Evidence-based stewardship interventions with the strongest outcome data include: prospective audit and feedback (PAF) by an ID pharmacist/physician team — reducing broad-spectrum antibiotic use by 30–40%; prior authorization requirements for carbapenems and broad-spectrum cephalosporins — reducing targeted antibiotic use by 28%; de-escalation protocols driven by culture results — reducing MRSA screening and carbapenem use; and IV-to-oral conversion programs reducing hospital LOS by 1.5 days. Diagnostic stewardship — specifically procalcitonin-guided discontinuation of antibiotics in sepsis (PRORATA trial, 2010; multiple confirmatory trials since) — reduces antibiotic duration by 2 days without mortality harm.
Infection Prevention: The Upstream Solution
No antimicrobial strategy succeeds without robust infection prevention. Contact precautions with proper PPE, environmental cleaning with EPA-registered disinfectants against ESKAPE pathogens, chlorhexidine gluconate (CHG) bathing for ICU patients, and catheter/central line bundles remain the foundation of HAI prevention. Healthcare facilities implementing or upgrading infection control programs can source comprehensive PPE, examination gloves, and environmental disinfection supplies through our PPE catalog and medical gloves section. Proper hand hygiene infrastructure — including antimicrobial soap and alcohol-based hand rub at point-of-care — remains the single highest-impact, lowest-cost intervention available.
